Transcriptome data of multiple sclerosis patients receiving fingolimod therapy
Ontology highlight
ABSTRACT:
ORGANISM(S): Homo sapiens
SUBMITTER: Michael Hecker
PROVIDER: E-GEOD-73174 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
Similar Datasets
Project description:We analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS). Affymetrix Human Transcriptome Arrays (HTA) 2.0 were used to obtain gene expression profiles of immune cell populations from 10 RRMS patients within the first 3 months of fingolimod treatment. This GEO entry provides the Affymetrix HTA 2.0 microarray data of peripheral blood CD8+ cells, preprocessed according to the gene level workflow. EDTA blood samples were taken from all patients immediately before first and second fingolimod administration as well as after 3 months of therapy. Total RNA of CD8+ cells positively selected from each blood sample was extracted, labeled and hybridized to high-density Affymetrix HTA 2.0 microarrays to quantify the transcript levels.
2015-09-19 | E-GEOD-73081 | biostudies-arrayexpress
Project description:We analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS). Affymetrix Human Transcriptome Arrays (HTA) 2.0 were used to obtain gene expression profiles of immune cell populations from 10 RRMS patients within the first 3 months of fingolimod treatment. This GEO entry provides the Affymetrix HTA 2.0 microarray data of peripheral blood CD8+ cells, preprocessed according to the exon level workflow. EDTA blood samples were taken from all patients immediately before first and second fingolimod administration as well as after 3 months of therapy. Total RNA of CD8+ cells positively selected from each blood sample was extracted, labeled and hybridized to high-density Affymetrix HTA 2.0 microarrays to quantify the transcript levels.
2015-09-19 | E-GEOD-73172 | biostudies-arrayexpress
Project description:We analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS). Affymetrix Human Transcriptome Arrays (HTA) 2.0 were used to obtain gene expression profiles of immune cell populations from 10 RRMS patients within the first 3 months of fingolimod treatment. This GEO entry provides the Affymetrix HTA 2.0 microarray data of peripheral blood CD4+ cells, preprocessed according to the gene level workflow. EDTA blood samples were taken from all patients immediately before first and second fingolimod administration as well as after 3 months of therapy. Total RNA of CD4+ cells positively selected from each blood sample was extracted, labeled and hybridized to high-density Affymetrix HTA 2.0 microarrays to quantify the transcript levels.
2015-09-19 | E-GEOD-73079 | biostudies-arrayexpress
Project description:We analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS). Affymetrix Human Transcriptome Arrays (HTA) 2.0 were used to obtain gene expression profiles of immune cell populations from 10 RRMS patients within the first 3 months of fingolimod treatment. This GEO entry provides the Affymetrix HTA 2.0 microarray data of peripheral blood CD4+ cells, preprocessed according to the exon level workflow. EDTA blood samples were taken from all patients immediately before first and second fingolimod administration as well as after 3 months of therapy. Total RNA of CD4+ cells positively selected from each blood sample was extracted, labeled and hybridized to high-density Affymetrix HTA 2.0 microarrays to quantify the transcript levels.
2015-09-19 | E-GEOD-73080 | biostudies-arrayexpress
Project description:This study looked to identify miRNAs regulating gene expression modules identified using weighted gene correlation network analysis in white cell subsets isolated from patients with immune-mediated disease and healthy controls.
2022-03-29 | E-MTAB-11565 | biostudies-arrayexpress
Project description:Gene expression microarray profiling was performed on peripheral blood leukocyte subsets (CD4+ T cells, CD8+ T cells, CD14+ monocytes, CD16+ neutrophils, CD19+ B cells) from healthy controls, patients with flaring autoimmune disease, and in patients with autoimmune disease following treatment, either 0 months (i.e. pre-treatment), or 3 or 12 months (into treatment).
2016-02-25 | E-MTAB-3554 | biostudies-arrayexpress
Project description:CD4+ T cells, CD8+ T cells, CD14+ monocytes, and CD16+ neutrophils from the peripheral blood of 5 healthy individuals were isolated and their ex vivo transcriptomic profiles measured.
2016-06-23 | E-MTAB-4887 | biostudies-arrayexpress
Project description:Enhancers are powerful regulatory regions, important for development and the maintenance of differentiated cells and tissues. Here, we generate global maps for two enhancer-associated histone marks, H3K4me1 and H3K27ac for a number of major human blood cell types. This data was generated to show that capped RNAs transcribed bidirectionally can identify known and novel enhancers in vivo. ChIP-seq of 2 histone marks in human blood monocytes, CD19+ B cells, CD8+ T cells, CD4+CD25-CD45RA+ naive T cells, & NK cells
2014-02-28 | E-GEOD-40668 | biostudies-arrayexpress
Project description:Host directed therapies against HIV-1 are thought to be critical for long term containment of the HIV-1 pandemic but remain elusive. Since HIV-1 infects and manipulates important effectors of both the innate and adaptive immune system, identifying modulations of the host cell systems in humans during HIV-1 infection may be crucial for the development of immune based therapies. Here, we quantified the changes of the proteome in human CD4+ T cells upon HIV-1 infection, both in vitro and in vivo. A SWATH-MS approach was used to measure the proteome of human primary CD4+ T cells infected with HIV-1 in vitro as well as CD4+ T cells from HIV-1 infected patients with paired samples on and off antiretroviral treatment. In the in vitro experiment, the proteome of CD4+ T cells was quantified over a time course following HIV-1 infection. 1,725 host cell proteins and 4 HIV-1 proteins were quantified, with 145 proteins changing significantly during the time course. Changes in the proteome peaked 24 hours after infection, concomitantly with significant HIV-1 protein production. In the in vivo branch of the study, CD4+ T cells from viremic patients and those with no detectable viral load after treatment were sorted and the proteomes quantified. We consistently detected 895 proteins, 172 of which were considered to be significantly different between viraemic patients and patients undergoing successful treatment. The proteome of in vitro infected CD4+ T cells was modulated on multiple functional levels, including TLR-4 signalling and the type 1 interferon signalling pathway. Perturbations in the type 1 interferon signalling pathway were recapitulated in CD4+ T cells from patients. The study shows that proteome maps generated by SWATH-MS indicate a range of functionally significant changes in the proteome of HIV infected human CD4+ T cells. Exploring these perturbations in more detail may help identify new targets for immune based interventions.
2017-02-28 | PXD005234 | Pride
Project description:Isocitrate dehydrogenase (IDH) mutations, a hallmark of gliomagenesis, result in the production of the oncometabolite R-2-hydroxyglutarate (R-2-HG) which is thought to promote tumorigenesis via DNA methylation. Here we identify an additional immunosuppressive activity of R-2-HG: Tumor cell-derived R-2-HG is taken up by T-cells where it induces a strong and immediate perturbation of calcium- and ATP-dependent signaling events, and polyamine biosynthesis. This results in a profound suppression of antigen-specific T-cell activation and effector cytokine production in experimental mouse and human systems. In a large cohort of WHO grade II and III gliomas, IDH1 mutant tumors display reduced infiltration by T-cells compared to IDH1 wildtype tumors. Spontaneous and induced mutation-specific antitumor immunity to syngeneic IDH1-mutant tumors in MHC-humanized mice is improved by isolated genetic ablation of the neomorphic enzymatic function of mutant IDH1. Taken together, these data attribute a novel, fundamentally non-tumor-cell-autonomous role of an oncometabolite in shaping the tumor immune microenvironment. We investigated the effects of exogenous R-2-HG on primary human T cells.
2016-07-27 | E-GEOD-84849 | biostudies-arrayexpress